Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. Our technology platforms include a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, we have a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb and Immune Design Corp.
Oxford, GB
Size (employees)
247 (est)
Oxford Biomedica was founded in 1995 and is headquartered in Oxford, GB
Report incorrect company information

Oxford Biomedica Office Locations

Oxford Biomedica has an office in Oxford
Oxford, GB (HQ)
Transport Way
Show all (1)
Report incorrect company information

Oxford Biomedica Financials and Metrics

Oxford Biomedica Financials

Oxford Biomedica's revenue was reported to be £27.78 m in FY, 2016 which is a 74.6% increase from the previous period.

Revenue (FY, 2016)

27.8 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

15.9 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(16.6 m)

EBITDA (FY, 2016)

(7.6 m)

EBIT (FY, 2016)

(11.3 m)

Market capitalization (31-Oct-2017)

276.4 m

Closing share price (31-Oct-2017)


Cash (31-Dec-2016)

15.3 m
Oxford Biomedica's current market capitalization is £276.4 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


7.2 m18.4 m19.1 m11.2 m7.7 m7.8 m5.4 m13.6 m15.9 m27.8 m

Revenue growth, %


Cost of goods sold

449 k1.3 m437 k593 k555 k667 k1.1 m4.4 m5.8 m11.8 m

Gross profit

6.8 m17.1 m18.7 m10.6 m7.2 m7.1 m4.2 m9.2 m10.1 m15.9 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


11 m8.1 m6.8 m6.7 m6.8 m9 m2.2 m14.2 m9.4 m15.3 m

Accounts Receivable

91 k106 k88 k1.8 m187 k315 k1.7 m4 m8.5 m4.9 m


680 k1.4 m2.7 m2.2 m

Current Assets

45.4 m31.2 m32.2 m18.2 m18.8 m17.6 m6.9 m22.8 m25.7 m27.4 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(15.3 m)(10 m)(3.5 m)(10.3 m)(12.6 m)(8.7 m)(11.1 m)(8.7 m)(13 m)(16.6 m)

Cash From Operating Activities

6.3 m(16 m)3.3 m(12.8 m)(13 m)(10 m)(11 m)(6 m)(13.1 m)(5.1 m)

Cash From Financing Activities

345 k611 k396 k303 k18.6 m10.3 m23.6 m25 m17.5 m

Net Change in Cash

2.9 m(2.8 m)(1.3 m)(147 k)185 k2.1 m(6.8 m)12 m(4.8 m)6 m
GBPY, 2016


112.5 k

Financial Leverage

4.5 x
Show all financial metrics

Oxford Biomedica Operating Metrics

Oxford Biomedica's Clinical Programs was reported to be 114 in FY, 2015.
FY, 2015

Clinical Programs


Patents Issued

Show all operating metrics
Report incorrect company information